Chemistry:EHP-102
From HandWiki
EHP-102, also known as VCE-003.2, is a cannabinoid CB2 receptor agonist and PPARγ agonist which is under development for the treatment of Parkinson's disease and Huntington's disease.[1][2][3][4] It is taken orally.[1] The drug is a derivative of cannabigerol (CBG).[4] It is under development by Emerald Health Sciences.[1][2][3] As of February 2024, it is in the preclinical research stage of development for both Parkinson's disease and Huntington's disease, but no recent development has been reported for Huntington's disease.[1][2][3]
See also
- List of investigational Parkinson's disease drugs
References
- ↑ 1.0 1.1 1.2 1.3 "EHP 102". 28 February 2024. https://adisinsight.springer.com/drugs/800057365.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on EHP-102 with Synapse". 24 May 2025. https://synapse.patsnap.com/drug/f361bd09f42348e78e96eeabd5ab9a5f.
- ↑ 3.0 3.1 3.2 "Medical Cannabis Pioneers Stake Their Claims: Across the medical cannabis frontier, natural cannabinoids, synthetic analogues, rationally designed ligands, and prodrugs are being developed". Genetic Engineering & Biotechnology News 40 (3): 52–55. 1 March 2020. doi:10.1089/gen.40.03.14. ISSN 1935-472X.
- ↑ 4.0 4.1 "VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease". Scientific Reports 6. July 2016. doi:10.1038/srep29789. PMID 27430371.
| Receptor (ligands)</small> |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transporter (modulators) |
| ||||||||||||
| Enzyme (modulators) |
| ||||||||||||
| Others |
| ||||||||||||
| |||||||||||||
| PPARα |
|
|---|---|
| PPARδ | |
| PPARγ |
|
| Non-selective | |
 | 0.00  (0 votes) |
